Condition: T Cell Lymphoma · T-cell Lymphoma · Sponsor: Yale University
Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T-cell lymphoma including patients with Adult T-cell leukemia/lymphoma (ATLL).
This description comes directly from the study's public registry record.
Carole Ramm · (203) 785-4095 · carole.ramm@yale.edu
Stephanie Ladd · 954-895-0576 · stephanie.ladd@yale.edu
Always discuss trial participation with your own doctor first.
| Yale Cancer Center, Clinical Trials Office | New Haven, Connecticut, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05996185